Literature DB >> 34995873

Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.

Amy M Linabery1, Michelle A Roesler2, Michaela Richardson2, Erica D Warlick3, Phuong L Nguyen4, Adina M Cioc5, Jenny N Poynter6.   

Abstract

BACKGROUND: Autoimmune diseases and hematopoietic malignancies are known to cluster within individuals, suggesting intertwined etiologies. A limited number of studies have evaluated pre-existing medical conditions as risk factors for myelodysplastic syndromes (MDS). We evaluated associations between autoimmune disease and other medical conditions and risk of MDS.
METHODS: Cases were identified through the Minnesota Cancer Reporting System. Controls were identified through the Minnesota State driver's license/identification card list. History of autoimmune disease and other medical conditions was based on self-report; proxy interviews were not conducted. Unconditional logistic regression was used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CI).
RESULTS: We included 395 cases and 694 controls. Cases were significantly more likely to report a diagnosis of any autoimmune disease when compared with controls (aOR=1.41, 95% CI: 1.05-1.89) after adjustment for age, sex, education, NSAID use, exposure to benzene and body mass index. When we evaluated specific autoimmune conditions, a statistically significant association was observed for hypothyroidism (aOR=2.16, 95% CI: 1.39-3.34) and odds ratios were elevated for inflammatory bowel disease (aOR=1.75) and systemic lupus erythematosus (SLE; aOR=3.65), although these associations did not reach statistical significance. Presence of an autoimmune condition did not impact overall survival (p = 0.91).
CONCLUSION: Our results validate previous findings of an association between autoimmune disease and MDS. Further studies are required to determine whether this association is due to shared etiology, treatment for autoimmune diseases, or altered immune surveillance or bone marrow damage caused by the autoimmune condition.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Chronic immune stimulation; Myelodysplastic syndrome; Risk factor

Mesh:

Year:  2022        PMID: 34995873      PMCID: PMC8792352          DOI: 10.1016/j.canep.2021.102090

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  44 in total

1.  Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.

Authors:  Lesley A Anderson; Shahinaz Gadalla; Lindsay M Morton; Ola Landgren; Ruth Pfeiffer; Joan L Warren; Sonja I Berndt; Winnie Ricker; Ruth Parsons; Eric A Engels
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

2.  Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers.

Authors:  Benjamin L Ebert; Peter Libby
Journal:  Ann Intern Med       Date:  2018-05-29       Impact factor: 25.391

Review 3.  Occupational exposures and haematological malignancies: overview on human recent data.

Authors:  Alexis Descatha; Arash Jenabian; Françoise Conso; Jacques Ameille
Journal:  Cancer Causes Control       Date:  2005-10       Impact factor: 2.506

4.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.

Authors:  Amanda B Wilson; Tuhina Neogi; Marianne Prout; Susan Jick
Journal:  Cancer Epidemiol       Date:  2014-09-02       Impact factor: 2.984

6.  Autoimmune diseases and myelodysplastic syndromes.

Authors:  Rami S Komrokji; Austin Kulasekararaj; Najla H Al Ali; Shahram Kordasti; Emily Bart-Smith; Benjamin M Craig; Eric Padron; Ling Zhang; Jeffrey E Lancet; Javier Pinilla-Ibarz; Alan F List; Ghulam J Mufti; Pearlie K Epling-Burnette
Journal:  Am J Hematol       Date:  2016-04-04       Impact factor: 10.047

7.  Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.

Authors:  Ling Lv; Guowei Lin; Xiang Gao; Cuie Wu; Junmin Dai; Yongchen Yang; Hejian Zou; Hengjuan Sun; Minghua Gu; Xi Chen; Hua Fu; Liming Bao
Journal:  Am J Hematol       Date:  2011-02       Impact factor: 10.047

8.  Risk factors of myelodysplastic syndromes: a case-control study.

Authors:  S S Strom; Y Gu; S K Gruschkus; S A Pierce; E H Estey
Journal:  Leukemia       Date:  2005-11       Impact factor: 11.528

9.  A case-control study of myelodysplastic syndromes in Belgrade (Serbia Montenegro).

Authors:  Tatjana Pekmezovic; Nada Suvajdzic Vukovic; Darija Kisic; Anita Grgurevic; Andrija Bogdanovic; Mirjana Gotic; Milena Bakrac; Nenad Brkic
Journal:  Ann Hematol       Date:  2006-05-12       Impact factor: 3.673

Review 10.  Hematopoietic malignancies and related disorders among benzene-exposed workers in China.

Authors:  L B Travis; C Y Li; Z N Zhang; D G Li; S N Yin; W H Chow; G L Li; M Dosemeci; W Blot; J F Fraumeni
Journal:  Leuk Lymphoma       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.